Many mutations in receptor kinases that lead to cancer allow the receptor to dimerize and become activated, even in the absence of signaling molecules. An example is a mutant form of the egf receptor kinase called her2/neu. An antibody that prevents dimerization of her2/neu receptor kinases is being tested for its effectiveness in preventing cancer. At which stage does this drug work?.